Inhaled insulin has been associated with lower weight gain in type 2 diabetes and less hypoglycemia compared to subcutaneous insulin but generally demonstrates lower glycemic efficacy compared to subcutaneous insulin therapy [136]. This evidence concerns the gene INS and type 2 diabetes mellitus.